Dr. Panagiotis Papageorgis is a Professor of Molecular Biology and currently serves as the Dean of the School of Sciences at European University Cyprus. He received his B.Sc. in Biology from the National and Kapodistrian University of Athens in 2003 and his Ph.D. in Cell and Molecular Biology/Genetics and Genomics from Boston University School of Medicine, USA, in 2009. He has worked as a postdoctoral fellow at the University of Cyprus and as a visiting scholar at Boston University School of Medicine and MGH/Harvard Medical School. He is a member of several professional bodies, including the American and European Associations for Cancer Research, a national representative of the Health configuration in the Horizon Europe program committee and a member of the national committee for the protection of animals used for scientific purposes. He has published 50 papers in referred journals and 4 book chapters and has more than 3300 citations (Google Scholar, h-index 27, as of 12/2022) and he was included in the list of the top 2% of the world’s scientists for 2020 and 2021, as announced by Stanford University. He is also the recipient of the prestigious “Young Researcher Award” for 2015 from the Cyprus Research Promotion Foundation. He is the Director of the Basic and Translational Cancer Research Center and the Head of the “Tumor Microenvironment, Metastasis and Experimental Therapeutics” research group. He currently runs 4 active research projects funded by the Research and Innovation Foundation, either as Coordinator or as Partner, of approximately 500,000 euros. His overall research interests include the elucidation of the molecular events that drive cancer progression at various stages of the metastatic cascade, including dormancy. He is also interested in deciphering the roles of the tumor microenvironment (TME), including immune cells, fibroblasts, extracellular matrix (ECM) components and secreted cytokines, like TGFβ, in regulating the metastatic process. Finally, his group is developing various therapeutic methodologies, including drug repurposing and combinatorial treatments, to remodel the TME and improve the delivery and efficacy of chemo-, nano- and immunotherapies using 3D cultures, organoids and animal tumor models.